Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

BACKGROUND: Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS: In this phase 1 study involving patients with relapsed or refractory multiple myeloma, we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Raje, Noopur, Berdeja, Jesus, Lin, Yi, Siegel, David, Jagannath, Sundar, Madduri, Deepu, Liedtke, Michaela, Rosenblatt, Jacalyn, Maus, Marcela V., Turka, Ashley, Lam, Lyh-Ping, Morgan, Richard A., Friedman, Kevin, Massaro, Monica, Wang, Julie, Russotti, Greg, Yang, Zhihong, Campbell, Timothy, Hege, Kristen, Petrocca, Fabio, Quigley, M. Travis, Munshi, Nikhil, Kochenderfer, James N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202968/
https://ncbi.nlm.nih.gov/pubmed/31042825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1817226
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados